

69

CONGRESO NACIONAL

SOCIEDAD ESPAÑOLA DE FARMACIA HOSPITALARIA

A CORUÑA

17-19 OCT 24

MEDICATION WITHOUT HARM:

WHAT IF I HAD BEEN EMPOWERED?

Sue Sheridan, MIM, MBA, DHL
Co-Founder, PFPS US



Patients for Patient Safety (PFPS) US



OUR VISION

- A world where no one is harmed in health care and every patient receives safe and respectful care, at all times and everywhere.

OUR MISSION


Implement the recommendations of the World Health Organization's Global Action Plan for Patient Safety 2021-2030 in the U.S.

PFPS US Champions

Campeones de PFPS US



What brings me here: Pat's Story



Medication safety during transitions of care
Medication safety in polypharmacy
Medication safety in high-risk situations

What if I had been empowered?

..... by educational tools/materials that had been co-produced by pharmacists AND patients and families with experience in polypharmacy errors?



... to participate in joint decision-making?

...to participate in discharge planning for smooth transitions in care?

.... with information about possible side effects of the narcotics, what to look for and actions to take?

to report the medication error so others would not suffer similar events?

Carole's Story



Medication safety in high-risk situations

What if Carole and Lindsay had been empowered?

..... by health care policies that required DPD screening that had been co-produced by pharmacists WITH patients and families with experience in harm from Xeloda?



... to participate in informed consent?


..... with education about DPD screening and the potential toxic side effects of Xeloda?

.... to report the medication error so that others would not suffer similar events?

..... through awareness-raising campaigns developed by patient organizations and pharmacists?

3 levels of patient empowerment in medication safety

Patients and Families Participate: In medication safety during care



Patients participate with
clinicians , nurses and
pharmacists in
medication safety

Patients and patient
associations participate in
awareness-raising,
medication safety
advocacy, and educating
others

Patients and patient
associations participate in
the co-production of
solutions to improve
medication safety

5 Momentos Clave para la utilización segura de los medicamentos



Antes de COMENZAR a tomar un medicamento

- ▶ ¿Cómo se llama y para qué sirve?
- ▶ ¿Cuáles son sus posibles efectos secundarios y qué tengo que hacer si los observo?



Cuando TOMO el medicamento

- ▶ ¿Cuándo y cómo debo tomar este medicamento y qué dosis debo tomar cada vez?
- ▶ ¿Qué debo hacer si me olvido de tomar una dosis?



AL AÑADIR otro medicamento

- ▶ ¿He entendido la necesidad de tomar otro medicamento más?
- ▶ ¿Este nuevo medicamento afecta o interfiere con el resto de mi tratamiento?



Cuando REVISAN mi medicación

- ▶ ¿Mantengo una lista actualizada con todos los medicamentos y productos que tomo?
- ▶ ¿Estoy tomando algún medicamento que ya no necesito?



Antes de FINALIZAR la toma de un medicamento

- ▶ ¿Cuándo debo dejar de tomar cada medicamento?
- ▶ Si tengo que suspender mi medicación por un efecto secundario, ¿dónde y a quién debo informar?

Patients and Patient Associations Participate: In awareness-raising, advocacy, and education

Patients participate with
clinicians , nurses and
pharmacists in
medication safety

Patients and patient
associations participate in
awareness-raising,
medication safety
advocacy, and educating
others

Patients and patient
associations participate in
the co-production of
solutions to improve
medication safety

Patients and Patient Associations Participate in:



Increasing awareness of medication safety and reporting systems and collecting and curating patient stories




Developing and disseminating patient education materials and tools on medication safety.



Building capacity and mobilizing advocates for medication safety

Advocates for Universal DPD/DPYD Testing

<https://test4dspd.org>



Advocates for Universal
DPYD Genetic Testing

Chemotherapy Treatment Warning Signs

Moderate to severe reaction on your
first or second round of 5-FU
(Fluorouracil) or Capecitabine

Why Get Tested First?



HOW TO BE SAFE

You Can Minimize Your Risk Of Severe Toxicity

by undergoing *DPYD* genetic testing prior to
the start of fluoropyrimidine based
chemotherapy.



Patient and Patient Associations Participate: In the co-production of solutions to improve medication safety

Patients participate with
clinicians , nurses and
pharmacists in
medication safety

Patients and patient
associations participate in
awareness-raising,
medication safety
advocacy, and educating
others

Patients and patient
associations participate in
the co-production of
solutions to improve
medication safety

Patients, families and patient associations: participate in collaborations



Medication safety policies, legislation, and guidelines



National medication safety alerts



Packaging, labeling, and other patient-centered drug safety issues



Advocates for Universal DPD/DPYD Testing

<https://test4dspd.org>

July 15, 2021 • Volume 26 Issue 14



Acute Care

ISMP Medication Safety Alert!

Educating the Healthcare Community About Safe Medication Practices

Screening for dihydropyrimidine dehydrogenase (DPD) deficiency in fluorouracil patients: Why not?



ISMP is aware of several reports of patients who suffered severe toxicity or even death from the fluoropyrimidine chemotherapy drug fluorouracil and capecitabine (XELODA), an oral prodrug that is metabolized to fluorouracil after ingestion. These patients had a genetic condition called dihydropyrimidine dehydrogenase (DPD) deficiency.

Citizen Petition

Citizen Petition to the US Food and Drug Administration (FDA) requesting the addition of pre-screening and dose adjustment practices to the drug labels for fluorouracil and

accepted the petition in November 2020. Offer your comments.

Legislation

NJ Assembly Bill A986:

Requires physician to offer to test patients for dihydropyrimidine Dehydrogenase deficiency prior to undergoing chemotherapy

- https://www.njleg.state.nj.us/2020/Bills/A1000/986_R1.PDF
- Reported out of Assembly Health Committee with Amendments, and Referred to Assembly Appropriations Committee

American Society of Pharmacovigilance

4th cause



How can hospital pharmacists play a crucial role in engaging with patients for safe medication?

Provide information and invite patients and caregivers to participate in safe medication and to ask questions

Participate with your patients in decision-making and informed consent

Involve your patients in medication review and reconciliation at admission, transfer and discharge

Participate in multidisciplinary clinical care teams and ward rounds

Establish medication reporting systems to which patients can report unsafe medication experiences

Involve patients in the development of solutions and policies for medication safety

"Patient participation and empowerment is perhaps the most powerful tool for improving patient safety"

WHO Global Patient Safety Action Plan 2021-2022



It is a question of will.....



69 CONGRESO
NACIONAL
SOCIEDAD ESPAÑOLA DE
FARMACIA HOSPITALARIA

A CORUÑA 17-19 OCT 24



A CORUÑA
17-19 OCT 24

Gracias por su atención

Ssheridan@pfps.us

69

**CONGRESO
NACIONAL**

SOCIEDAD ESPAÑOLA DE
FARMACIA HOSPITALARIA

